Ticker > Company >

Asston Pharma share price

Asston Pharmaceuticals Ltd.

BSE: 544445 SECTOR: Pharmaceuticals & Drugs  65   0   0

117.35
-6.15 (-4.98%)
BSE: Today, 10:33 AM

Price Summary

Today's High

₹ 126

Today's Low

₹ 117.35

52 Week High

₹ 125

52 Week Low

₹ 113.05

FinStar

Ownership Below Par
Stock price may face volatility due to ownership structure.
ValuationAttractive
The stock is considerably attractive based on intrinsic value.
EfficiencyExcellent
The company knows very well the utilization of its assets.
FinancialsVery Stable
The company possesses stable growth history and manageable debt.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

99.89 Cr.

Enterprise Value

106.95 Cr.

No. of Shares

0.85 Cr.

P/E

23.1

P/B

2.61

Face Value

₹ 10

Div. Yield

0 %

Book Value (TTM)

₹  44.97

CASH

0.2 Cr.

DEBT

7.26 Cr.

Promoter Holding

-

EPS (TTM)

₹  5.08

Sales Growth

60.65%

ROE

50.56 %

ROCE

42.64%

Profit Growth

217.95 %

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.
* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year60.65%
3 Year37.66%
5 YearNA

Profit Growth

1 Year217.95%
3 Year239.43%
5 YearNA

ROE%

1 Year50.56%
3 Year51.84%

ROCE %

1 Year42.64%
3 Year35.58%

Debt/Equity

0.6771

Price to Cash Flow

-613.21

Interest Cover Ratio

7.0015

CFO/PAT (5 Yr. Avg.)

0

Shareholding Pattern

Investors List
 Share Holding Data is not available for this company.Report us
* Figures given above are % of equity capital

 Strengths

  • The company has shown a good revenue growth of 37.65890327955% for the Past 3 years.
  • Company has been maintaining healthy ROE of 51.8388% over the past 3 years.
  • Company has been maintaining healthy ROCE of 35.5823% over the past 3 years.

 Limitations

  • Company has high debtor days of 296.6529.
  • Company has negative cash flow from operations of -0.1629.
  • The company has a low EBITDA margin of 0% over the past 5 years.

Quarterly Result (All Figures in Cr.)

 Quarterly Data is not available for this company.Report us

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2022 Mar 2023 Mar 2024 Mar 2025
Net Sales 9.6 6.54 15.59 25.04
Total Expenditure 9.95 5.02 13.04 18.88
Operating Profit -0.36 1.52 2.55 6.16
Other Income 0.96 0.65 0.25 0.57
Interest 0.43 0.72 0.93 0.95
Depreciation 0.01 0.04 0.05 0.08
Exceptional Items 0 0 0 0
Profit Before Tax 0.16 1.41 1.82 5.7
Tax 0.05 0.36 0.46 1.37
Net Profit 0.11 1.06 1.36 4.33
Adjusted EPS (Rs.) 0.2 1.89 2.17 6.9

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2022 Mar 2023 Mar 2024 Mar 2025
Equity and Liabilities
Share Capital 0.7 0.7 0.78 6.27
Total Reserves 0.23 1.29 5.61 4.45
Borrowings 0.94 1.82 1.63 2.26
Other N/C liabilities 0.07 0.1 0.18 0.14
Current liabilities 7.56 9.79 12.06 14.99
Total Liabilities 9.49 13.69 20.26 28.1
Assets
Net Block 0.92 1.13 1.09 0.96
Capital WIP 0 0 0 0
Intangible WIP 0 0 0 0
Investments 0 0 0 0
Loans & Advances 1.19 1.2 0.13 0.13
Other N/C Assets 0 0.67 0.71 0
Current Assets 7.38 10.69 18.34 27.02
Total Assets 9.49 13.69 20.26 28.1
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2022 Mar 2023 Mar 2024 Mar 2025
Profit from operations 0.16 1.41 1.82 5.7
Adjustment 0.44 0.75 0.94 0.93
Changes in Assets & Liabilities -1.76 -2.46 -6.11 -6.79
Tax Paid -0.03 -0.01 -0.45 0
Operating Cash Flow -1.19 -0.32 -3.8 -0.16
Investing Cash Flow 0 -0.91 -0.01 0.87
Financing Cash Flow 1.29 1.21 3.69 -0.51
Net Cash Flow 0.1 -0.01 -0.12 0.19

Corporate Actions

Investors Details

 No Promoters Data available for this company.Report us
 No Investors Data available for this company.Report us

Annual Reports

Title Link
Title Link
 No Annual reports exist for this company.Report us

Ratings & Research Reports

TYPE AGENCY Link
TYPE AGENCY Link
 No Credit and Research reports exist for this company.Report us
TYPE AGENCY Link
TYPE AGENCY Link
 No Research reports exist for this company.Report us

Concalls & Presentations

TYPE QUARTER Link
TYPE QUARTER Link
 Currently we do not have any Presentation and Concall related to this company.Report us
TYPE QUARTER Link
TYPE QUARTER Link
 Currently we do not have any Presentation related to this company.Report us

Asston Pharma Stock Price Analysis and Quick Research Report. Is Asston Pharma an attractive stock to invest in?

The Indian healthcare sector is expected to reach US$ 372 billion by 2022, driven by rising incomes, greater health awareness, lifestyle diseases and increasing access to insurance. Healthcare has become one of India’s largest sectors - both in terms of revenue and employment.

Healthcare comprises hospitals, medical devices, clinical trials, outsourcing, telemedicine, medical tourism, health insurance, and medical equipment. The structure of the healthcare delivery system in India consists of three broad segments: Primary care, Secondary care, and Tertiary care.

  • Primary care is the first point of contact between the population and the healthcare service providers. For example, Sub-center (SC), Primary Health Centre (PHC) and Community Health Centre (CHC) which is more relevant to rural areas (PHC’s).
  • Secondary care providers inpatient as well as outpatient medical services and includes simple surgical procedures. For example, District level & Mid-sized hospitals.
  • Tertiary care is the third level of the healthcare delivery system in the country. These hospitals are specialized consultative healthcare infrastructure. For example, Single specialty and Multi-specialty hospitals.

While healthcare services are offered by the public as well as private sectors, in urban as well as rural areas, generally people prefer private hospitals over public hospitals for treatment of diseases, illness, and sickness. So, let’s look into Asston Pharma and its performance over the period of time. Asston Pharma stock price today is Rs 121.5.

  • Operating cash flow ratio: It measures the adequacy of a company’s cash generated from operating activities to pay off short-term financial obligations. Asston Pharma cash from the operating activity was Rs -0.1629 Cr.
     
  • Financial Strength: Health care organizations usually have high debt loads and low equity capital in their balance sheet. So, Debt to Equity ratio is important to analyze the company’s sustainability. Asston Pharma has a Debt to Equity ratio of 0.6771 , which is a strong indication for the company.
     
  • EPS growth: Investors should ensure the EPS figure is growing faster than revenue numbers because it indicates company management is increasing the efficiency with which it runs the company. In Asston Pharma , the EPS growth was 217.9429 % which is good for the company.
     
  • Operating profit margin: It determines a company's potential earnings. It assesses how well-managed a company with respect to its basic overhead costs and other operating expenses, Asston Pharma has OPM of 24.5986293491805 % which is a good sign for profitability.
     
  • ROE: Asston Pharma have a healthy ROE of 50.5558 %. ROE is an important financial parameter for hospitals & health care companies because they expand and grow rapidly. Therefore, ROE measures how efficiently a shareholder's fund is used for generating profits.
     
  • Share Price: - The current share price of Asston Pharma is Rs 121.5. One can use valuation calculators of ticker to know if Asston Pharma share price is undervalued or overvalued.
Last Updated on:
Brief about Asston Pharma
X